WEBINAR

April 17, 2025 (11:00am ET)


Fuelled by the global surge in type 2 diabetes and obesity, the GLP-1 market is set to explode from $20 billion in 2024 to $50 billion by 2030, offering vast opportunities for innovation. This webinar provides a deep dive into the latest advancements and best practices in GLP-1 drug development, covering the journey from early discovery synthesis, biology modelling to in-vitro and in vivo testing, and fostering a vibrant exchange of insights between academia and industry.

We'll also explore the shift from daily-multiple to once-weekly dosing, innovations in extended dosing regimens and dual/triple agonisms, and the potential of oral formulations. Join us to uncover interdisciplinary strategies in Biology, Chemistry, and DMPK that are shaping the future of GLP-1 drug development, highlighted through real-world case studies.


What you will discover:

The evolution of GLP-1 therapies: Emphasizing the transition from daily-multiple injections to once-weekly injections, significantly boosting patient compliance.
The Trajectory of GLP-1 Drug Development: Discussing advancements such as longer circulation, innovations in dual/triple agonisms, new indication explorations, and the potential of oral formulations.
In-vitro Assays: Development of in-vitro assays specifically designed for the bioanalysis of GLP-1 agonists and antagonists.
Disease Models: Exploration of NASH/MASH, Diabetes, and Diet-Induced Obesity (DIO) models.
Synthesis Strategies: Comparative insights into Solid Phase Synthesis and Liquid Phase Synthesis for GLP-1R.
Synthetic and Testing Differences: Insights into peptide vs. small-molecule GLP-1R agonists in both synthesis and testing fields.
ADME and PK of Polypeptides: comprehensive analysis of in vitro ADME properties and in vivo pharmacokinetic profiles.
Real-World Case Studies: discover best practices in Biology, Chemistry, and DMPK fields.

Register Now


Speakers:
1.png
Tao Ma, Ph.D.
Associate Professor
Beijing University of Chinese Medicine
2.png
Yuyan Chen, Ph.D.
Director of Chemistry
BioDuro
3.png
Zhe Zheng, Ph.D.
Lead of Discovery Biology (Jiangsu Site)
BioDuro
4.png
Haoqing Chen, Ph.D.
Lead of ADME
BioDuro
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all